Sex representation in trials relative to indication-specific disease burden in FDA-approved drugs (2015–2023)

Journal:
Nature Communications
Published:
DOI:
10.1038/s41467-026-74469-z
Affiliations:
2
Authors:
2
Go to article
Institutions Authors Share
University of California, Riverside (UCR), United States of America (USA)
1.500000
 0.75
University of California, Irvine (UCI), United States of America (USA)
0.500000
 0.25